Asia Pacific pharmaceutical contract manufacturing market will grow by 7.6% annually with a total addressable market cap of $489.1 billion over 2020-2030 owing to the rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity.
Highlighted with 38 tables and 53 figures, this 116-page report “Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country.
Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical Industry
• Biopharmaceutical Industry
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Active Pharmaceutical Ingredients (API)
• Branded API Manufacturing
• Generic API Manufacturing
Finished Dosage Formulations (FDF)
• Solid Dosage
• Oral Liquids
• Parenteral/Injectables
• Other FDFs
Secondary Packaging
Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Clinical Manufacturing
• Commercial Manufacturing
Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Sterile Products
• Non-Sterile Products
Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 26
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Asia Pacific Market by Category 41
3.1 Market Overview by Category 41
3.2 Pharmaceutical Industry 43
3.3 Biopharmaceutical Industry 44
4 Segmentation of Asia Pacific Market by Product 45
4.1 Market Overview by Product 45
4.2 Active Pharmaceutical Ingredients (API) 47
4.2.1 Branded API Manufacturing 48
4.2.2 Generic API Manufacturing 49
4.3 Finished Dosage Formulations (FDF) 50
4.3.1 Solid Dosage 52
4.3.2 Oral Liquids 53
4.3.3 Parenteral/Injectables 54
4.3.4 Other FDFs 55
4.4 Secondary Packaging 56
5 Segmentation of Asia Pacific Market by Phase 57
5.1 Market Overview by Phase 57
5.2 Clinical Manufacturing 59
5.3 Commercial Manufacturing 60
6 Segmentation of Asia Pacific Market by Type 61
6.1 Market Overview by Type 61
6.2 Sterile Products 63
6.3 Non-Sterile Products 64
7 Segmentation of Asia Pacific Market by Therapeutic Application 65
7.1 Market Overview by Therapeutic Application 65
7.2 Infectious Diseases 67
7.3 Oncology 68
7.4 Metabolic Disorders 69
7.5 Cardiovascular Disorders 70
7.6 Central Nervous System 71
7.7 Pulmonary Disorders 72
7.8 Gastrointestinal Disorders 73
7.9 Other Therapeutic Applications 74
8 Asia-Pacific Market 2019-2030 by Country 75
8.1 Overview of Asia-Pacific Market 75
8.2 Japan 78
8.3 China 81
8.4 Australia 84
8.5 India 86
8.6 South Korea 88
8.7 Rest of APAC Region 90
9 Competitive Landscape 92
9.1 Overview of Key Vendors 92
9.2 New Product Launch, Partnership, Investment, and M&A 95
9.3 Company Profiles 96
Aenova Group 96
Baxter BioPharma Solutions 98
Boehringer Ingelheim 99
Catalent Inc. 100
Famar S.A. 101
Hospira, Inc. 102
Jubilant Life Sciences Ltd. 103
Lonza Group 104
Patheon Inc. 105
Pfizer CentreSource 106
Recipharm AB 107
Vetter Pharma International GmbH 108
10 Investing in Asia Pacific Market: Risk Assessment and Management 109
10.1 Risk Evaluation of Asia Pacific Market 109
10.2 Critical Success Factors (CSFs) 112
Related Reports and Products 115
Key Players (this may not be a complete list and extra companies can be added upon request):
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
Ěý
Ěý
*If Applicable.
